Renal Cell Carcinoma Features Archive

General Oncology Reclassification of Variants of Uncertain Significance: A Q&A With Theodora Ross MD, PhD

Reclassification of Variants of Uncertain Significance: A Q&A With Theodora Ross MD, PhD

Dr Ross described how genomic reports may need to be updated to account for new insights into a variant's role in cancer.

General Oncology Using ctDNA to Predict Cancer Recurrence and Guide Therapy Selection

Using ctDNA to Predict Cancer Recurrence and Guide Therapy Selection

A ctDNA testing method has the capability to predict cancer recurrence, which could help guide therapy selections and uncover new drug development opportunities.

General Oncology Synthetic or Plant-Based Cannabis for Symptom Relief in Patients With Cancer: Do We Have Any Evidence?

Synthetic or Plant-Based Cannabis for Symptom Relief in Patients With Cancer: Do We Have Any Evidence?

In clinical practice, most physicians and nurse practitioners do not feel comfortable enough with their medical knowledge of cannabis to offer it to patients.

General Oncology Fall of Star Cancer Researcher Brings Broader Picture Into View

Fall of Star Cancer Researcher Brings Broader Picture Into View

Dr José Baselga failed to disclose his financial ties to pharmaceutical companies in top-tier journals, causing many to question whether conflicts of interest are being properly reported.

Renal Cell Carcinoma The Identification of a Potential Early Plasma Biomarker for Kidney Cancer

The Identification of a Potential Early Plasma Biomarker for Kidney Cancer

Researchers found that doubling in KIM-1 plasma concentrations was associated with an increased risk of developing RCC and poorer survival.

General Oncology Oncology Community Expresses Concern About Medicare Advantage Step-Therapy Policy

Oncology Community Expresses Concern About Medicare Advantage Step-Therapy Policy

More than 90 medical societies have called on the US government to reverse a policy allowing step therapy under Medicare Advantage.

General Oncology FDA Guidance: Expansion Cohort Trials Expected to Modernize Oncology Trials

FDA Guidance: Expansion Cohort Trials Expected to Modernize Oncology Trials

There is a push to create innovative adaptive trial designs that include more patients and, subsequently, more generalizable data.

Renal Cell Carcinoma Robotic Partial Nephrectomy Compared With Open, Laparoscopic Partial Nephrectomy

Robotic Partial Nephrectomy Compared With Open, Laparoscopic Partial Nephrectomy

A meta-analysis compared outcomes between the use of partial nephrectomy using a robotic surgical approach and open or laparoscopic partial nephrectomy.

Renal Cell Carcinoma Clues from DNA Repair Mechanisms Could Drive Novel Therapeutic Strategies

Clues from DNA Repair Mechanisms Could Drive Novel Therapeutic Strategies

Metabolites from the Krebs cycle were found to suppress the DNA-repair pathway required for the preservation of genomic integrity.

General Oncology Bispecific Antibodies in Cancer

Bispecific Antibodies in Cancer

Interest in these bioengineered antibodies has been rekindled by the striking success seen in the treatment of some cancers with immunotherapies.

General Oncology Cognitive Functioning Affects the Ability of Patients With Advanced Cancer to Give Informed Consent

Cognitive Functioning Affects the Ability of Patients With Advanced Cancer to Give Informed Consent

Approximately half of patients with advanced cancer who are enrolled in phase 1 clinical trials do not know the ultimate goal of the study.

Renal Cell Carcinoma Lower Costs of Pazopanib for Advanced RCC May Influence Drug Choice

Lower Costs of Pazopanib for Advanced RCC May Influence Drug Choice

Any new study of pazopanib or sunitinib must be placed in perspective of the changing treatment landscape and the market entrance of new immunotherapies.

General Oncology Triclosan and Cancer Risk: Is There a Link?

Triclosan and Cancer Risk: Is There a Link?

Some studies suggest triclosan could have oncogenic properties, but more research is needed to confirm a causal link.

General Oncology Is Genomic Medicine Failing Minority Patients?

Is Genomic Medicine Failing Minority Patients?

Racial minorities are poorly represented in genomic research databases, raising important questions about whether or not all patients will benefit equally from advances in precision oncology.

Renal Cell Carcinoma Heading Toward Personalized Management of Advanced Kidney Cancer

Heading Toward Personalized Management of Advanced Kidney Cancer

The heterogeneity of kidney cancer makes each of the tumors unique and treatment decisions based on tumor characteristics especially challenging.

General Oncology ARID1A Mutations Might Predict Tumor Response to Immunotherapy

ARID1A Mutations Might Predict Tumor Response to Immunotherapy

New findings bolster the case for the predictive utility of ARID1A mutations.

General Oncology Liquid Biopsies and Cancer Detection: New Test Assesses Levels of Circulating Proteins for Early-Stage Diagnosis

Liquid Biopsies and Cancer Detection: New Test Assesses Levels of Circulating Proteins for Early-Stage Diagnosis

A new test has been shown to be capable of identifying eight different cancers by assessing levels of circulating proteins along with mutations in cell-free DNA.

General Oncology Understanding Telomerase: Higher Quality Images Give Insight Into Developing New Agents for Inhibition

Understanding Telomerase: Higher Quality Images Give Insight Into Developing New Agents for Inhibition

Telomerase plays a crucial role in tumor proliferation, and a better understanding of its structure will pave the way for new drug development.

General Oncology Efficacy and Hyperemesis Syndrome Associated With Cannabinoid Use in Cancers ― In the Clinic

Efficacy and Hyperemesis Syndrome Associated With Cannabinoid Use in Cancers ― In the Clinic

Many clinical trials and systematic reviews note that the use of cannabinoids also comes with adverse events, including a clinical entity that has been gaining evidence in the literature over the last decade called cannabinoid hyperemesis syndrome.

Prostate Cancer Can Oncolytic Viruses Improve Immunotherapies?

Can Oncolytic Viruses Improve Immunotherapies?

Emerging evidence shows that injecting tumors directly into one tumor can trigger systemic antitumor immunity and immune attacks on untreated tumors elsewhere in the body.

General Oncology Clonally Transmissible Cancers in Nature

Clonally Transmissible Cancers in Nature

While a recent discovery of a series of communicable cancers has raised concerns, there has been no sign of readily transmittable cancer in people that could spread through a population the way the ones found in other species do.

Renal Cell Carcinoma Renal Cell Carcinoma: How Biomarkers Could Affect Drug Development

Renal Cell Carcinoma: How Biomarkers Could Affect Drug Development

An example of where biomarkers may help to select the best medication for a patient and also assist in drug development is the tyrosine kinase inhibitor (TKI) dovitinib for renal cell carcinoma (RCC).

Renal Cell Carcinoma No Single Gene Seems to Drive Renal Cell Carcinoma Metastasis

No Single Gene Seems to Drive Renal Cell Carcinoma Metastasis

Recent research indicates that there were no significant differences in the genomic landscape of clear cell RCC primary tumors and metastases, or between the different sites of metastases.

General Oncology The Hunt for Effective Anticancer Vaccines

The Hunt for Effective Anticancer Vaccines

Researchers are hotly pursuing 2 distinct biological paths that show remarkable promise in the hunt for an effective anticancer vaccine.

Renal Cell Carcinoma Does Sunitinib Have A Future in Renal Cell Carcinoma Treatment?

Does Sunitinib Have A Future in Renal Cell Carcinoma Treatment?

Immunotherapy may supplant sunitinib in RCC, except for in patients who cannot tolerate checkpoint inhibition.

General Oncology HIV-Associated Cancers: A Paradigm Shift?

HIV-Associated Cancers: A Paradigm Shift?

Many HIV-associated cancers develop with the help of oncoviruses — some of which are sexually transmitted.

General Oncology Anticancer Immunotherapy to Circumvent Tumor Resistance to Immune Checkpoint Inhibitors

Anticancer Immunotherapy to Circumvent Tumor Resistance to Immune Checkpoint Inhibitors

Most tumors do not respond, or evolve resistance, to immune checkpoint inhibition. Now, researchers at Johns Hopkins have engineered a new class of cancer immunotherapy agents designed to short-circuit key mechanisms of tumors' disruption and evasion of immune system attack.

General Oncology Phase 1 Trials: Therapy, Not Just Science

Phase 1 Trials: Therapy, Not Just Science

Phase 1 trials should be considered therapeutic options for some patients.

Side Effect Management Immunotherapy and the Risk of Myocarditis

Immunotherapy and the Risk of Myocarditis

The risk should not discourage patients with cancer from taking these potentially life-extending therapies.

Renal Cell Carcinoma Combinations: The Future of Renal Cell Carcinoma Treatment?

Combinations: The Future of Renal Cell Carcinoma Treatment?

Several phase 3 clinical trials are likely to identify new frontline standards of care.

Renal Cell Carcinoma Targeted and Immunotherapies for Metastatic Renal Cell Carcinoma

Targeted and Immunotherapies for Metastatic Renal Cell Carcinoma

VEGF and PD-1 pathway inhibitors show promising improvements compared with single-agent VEGF pathway inhibitors.

General Oncology Clostridium Difficile Infection in Patients With Cancer — In the Clinic

Clostridium Difficile Infection in Patients With Cancer — In the Clinic

While CDI is becoming more common in all hospitalized patients, patients with cancer appear to be at an elevated risk.

General Oncology Can A Consortium of Hospitals Help To Reduce Drug Prices?

Can A Consortium of Hospitals Help To Reduce Drug Prices?

To help curb drug prices, a consortium of hospital groups recently announced plans to form their own nonprofit drug company.

General Oncology Larotrectinib: Promising for All TRK-Positive Tumors

Larotrectinib: Promising for All TRK-Positive Tumors

Larotrectinib may have durable antitumor activity in patients with TRK fusion-positive cancers, regardless of tumor type.

Renal Cell Carcinoma Curbing Regulatory Capture: A Q&A With Bishal Gyawali, MD, PhD

Curbing Regulatory Capture: A Q&A With Bishal Gyawali, MD, PhD

Cancer Therapy Advisor asked Dr Gyawali, who coauthored a viewpoint just published in JAMA Oncology, to discuss the FDA's approval of sunitinib, and whether it is an example of what he calls "regulatory capture" in medicine.

General Oncology Diagnosing Medicine's Intractable Gender Pay Gap

Diagnosing Medicine's Intractable Gender Pay Gap

The #MeToo movement has inspired many women to relate stories of harassment, and medicine is no exception.

Renal Cell Carcinoma VHL and the Risk for Renal Cell Carcinoma — In the Clinic

VHL and the Risk for Renal Cell Carcinoma — In the Clinic

Close to 60% of all patients with VHL will develop RCC or renal cysts.

Side Effect Management Managing Adverse Events in the Era of Immunotherapy

Managing Adverse Events in the Era of Immunotherapy

The novelty of immunotherapies means that physicians and patients lack extensive experience dealing with them.

Renal Cell Carcinoma Multidisciplinary Models for Treating Renal Cell Carcinoma

Multidisciplinary Models for Treating Renal Cell Carcinoma

A shift toward multidisciplinary care is inevitable for the treatment of locally advanced and metastatic RCC.

General Oncology Healthful Lifestyles and Cancer: Much More Than A Single Behavior

Healthful Lifestyles and Cancer: Much More Than A Single Behavior

A recent study is the first to demonstrate the cumulative effect of a large number of lifestyle behaviors.

General Oncology Cancer Immunosurveillance Comes of Age

Cancer Immunosurveillance Comes of Age

As oncologists learn to target the immune response to "self and non-self," a delicate therapy balance will eventually be achieved with predictable outcomes, benefits, and toxicity in the fight against cancer.

Renal Cell Carcinoma Renal Cell Carcinoma: Cost of Treatment May Negate Impact of Treatment Advances

Renal Cell Carcinoma: Cost of Treatment May Negate Impact of Treatment Advances

Access to treatment should be considered as important as the research leading to clinical improvements.

General Oncology Does Immune Checkpoint Inhibition Have A Dark Side?

Does Immune Checkpoint Inhibition Have A Dark Side?

Careful research is needed to ensure that immunotherapies activating T cells do not inadvertently fuel progression of T cell malignancies.

General Oncology Cannabis for Cancer: An Uncertain Future

Cannabis for Cancer: An Uncertain Future

While some researchers are attempting to determine whether cannabis has any anti-tumor activity, the FDA recommends that patients do not listen to websites touting the benefits of cannabidiol.

General Oncology Can Understanding the Gut Microbiome Improve Clinical Oncology?

Can Understanding the Gut Microbiome Improve Clinical Oncology?

Researchers hope to define what constitutes a functionally healthy microbiome not just in cancer, but across the health spectrum.

Renal Cell Carcinoma Too Soon To Declare Whether Immunotherapy Can Cure Metastatic RCC

Too Soon To Declare Whether Immunotherapy Can Cure Metastatic RCC

Though uncommon, complete responses are seen among patients with metastatic disease, but CRs seem to occur more often with immune checkpoint inhibitors.

General Oncology Cancer Drug Addiction: Prospects for Integrated Therapeutic Management

Cancer Drug Addiction: Prospects for Integrated Therapeutic Management

The drug addiction strategy must be broadened to account for non-addicted cells, sensitive or resistant, that remain after therapy. Much as selection should favor the development of drug resistant tumor cell lineages, it should also favor lineages that are resistant to addiction.

General Oncology Can Inhibiting Ubiquitin Target Undruggable Tumor Proteins?

Can Inhibiting Ubiquitin Target Undruggable Tumor Proteins?

A class of DUBs known as the ubiquitin-specific-processing proteases are involved in regulating the p53 signaling pathway and have been implicated in tumorigenesis and radiotherapy resistance.

General Oncology The Warburg Effect: Can Cancer Be Starved of Sugar?

The Warburg Effect: Can Cancer Be Starved of Sugar?

A recent study into the relationship between glucose and cancer cell proliferation may be helping to identify a therapeutic route to starve tumors without killing normal cells.

Renal Cell Carcinoma Smoking After Diagnosis Leads to Worse Renal Cell Carcinoma-specific Survival

Smoking After Diagnosis Leads to Worse Renal Cell Carcinoma-specific Survival

Cigarettes may favor VHL-intact RCC, but it is unclear whether cigarette smoking selects for more aggressive histology of RCC in a similar way to, for example, the TP53 mutation in lung cancer.

Renal Cell Carcinoma Overexpression of CKAP4 Linked With Poor Prognosis in Renal Cell Carcinoma

Overexpression of CKAP4 Linked With Poor Prognosis in Renal Cell Carcinoma

Overexpressed CKAP4 was significantly associated with tumor, nodal, and metastasis stages, as well as Fuhrman grades.

General Oncology Genetic Predisposition to Cancer: Where Are We Now?

Genetic Predisposition to Cancer: Where Are We Now?

In part 2 of a 2-part series, Bryant Furlow discusses advances in genome sequencing technologies and the resulting insights into associations between inherited germline mutations and cancer.

General Oncology Mobile Apps: The Future of Cancer Care?

Mobile Apps: The Future of Cancer Care?

From anxiety and pain self-management to side effect monitoring in clinical trials, mobile applications are revolutionizing oncology. Researchers say the technology is even transforming clinical trials themselves.

General Oncology Spontaneous Regression of Cancer: Explanations and Predictions

Spontaneous Regression of Cancer: Explanations and Predictions

Clifford Pukel, MD, discusses from an immunological standpoint the mysterious phenomenon of spontaneous regression.

Renal Cell Carcinoma Adjuvant Therapy in Renal Cell Carcinoma: Still Riddled With Unknowns

Adjuvant Therapy in Renal Cell Carcinoma: Still Riddled With Unknowns

About one-third of patients will experience disease recurrence after undergoing nephrectomy, and clinical trials exploring the use of adjuvant therapy in these patients produce conflicting results.

Renal Cell Carcinoma Pazopanib: Where Does It Stand as Adjuvant Therapy in Localized RCC?

Pazopanib: Where Does It Stand as Adjuvant Therapy in Localized RCC?

While renal cell carcinoma treatment continue to improve, it's unclear whether pazopanib should be used in the adjuvant setting.

General Oncology Establishing Links Between Germline Mutations and Oncogenesis

Establishing Links Between Germline Mutations and Oncogenesis

In part 1 of a 2-part series, Bryant Furlow discusses advances in the understanding of inherited cancer syndromes and screening techniques for early tumor detection in high-risk patients.

General Oncology Effective Communication With Patients Is Critical for Improved Quality of Life, Lower Costs

Effective Communication With Patients Is Critical for Improved Quality of Life, Lower Costs

Repeated active discussions with patients about distress, treatment options, and goals can both reduce costs and help to identify when aggressive treatment is no longer appropriate, according to hematologist/oncologist Stuart Goldberg, MD.

Renal Cell Carcinoma Multigene Test May Help Identify Hereditary Kidney Cancers

Multigene Test May Help Identify Hereditary Kidney Cancers

Hereditary kidney cancer syndromes are often diagnosed by astute clinicians who recognize that there is more to a patient's diagnosis then just the random event of getting cancer.

Renal Cell Carcinoma Sirolimus Use in Graft Versus Host Disease

Sirolimus Use in Graft Versus Host Disease

As more experience with sirolimus has been gained, it began to be used "off-label" to prevent rejection in multiple transplant recipients and is now being studied in the treatment of GVHD.

Renal Cell Carcinoma Telomere Length May Predict Renal Cell Carcinoma Risk in Patients with VHL

Telomere Length May Predict Renal Cell Carcinoma Risk in Patients with VHL

There are estimated to be 13 distinct hereditary renal cell carcinoma (RCC) syndromes, each of which is associated with specific germline mutations, including von Hippel-Lindau disease (VHL).

General Oncology Liquid Biopsies for Circulating Tumor Cells: A New Prognostic Tool?

Liquid Biopsies for Circulating Tumor Cells: A New Prognostic Tool?

While liquid biopsies could prove successful in monitoring treatments, these tests might also find early-stage cancers that, left alone, would never progress.

Renal Cell Carcinoma In Focus: Axitinib for Metastatic Renal Cell Carcinoma

In Focus: Axitinib for Metastatic Renal Cell Carcinoma

Axitinib is an efficacious drug among patients with metastatic RCC, though selecting the appropriate patients for treatment and the correct dose can be difficult.

Renal Cell Carcinoma microRNAs and the Future of Renal Cell Carcinoma Treatment

microRNAs and the Future of Renal Cell Carcinoma Treatment

With researchers around the world directing their attention at the role and potential of miRNAs in RCC diagnosis and therapy, our understanding of the molecules is accelerating.

General Oncology Malware in Medicine: Prevention Is Key to Protection

Malware in Medicine: Prevention Is Key to Protection

The race against malware is much the same as a war between an infectious agent and a host: it's a battle between hackers and security experts — and it's not at all clear who is winning.

General Oncology Drug-herb and Drug-drug Interactions in Oncology

Drug-herb and Drug-drug Interactions in Oncology

Mixed data highlight the need for researchers to conduct studies to understand the clinical, rather than just theoretical, risks of HDIs and DDIs.

General Oncology Immune-mediated Hepatitis: Challenges in Management

Immune-mediated Hepatitis: Challenges in Management

The incidence of immune-mediated hepatitis in patients receiving immunotherapy varies based on the agent and other concomitant medications, though it is not uncommon.

General Oncology Can the FDA Curb Drug Prices for Cancer Treatment?

Can the FDA Curb Drug Prices for Cancer Treatment?

The US Food and Drug Administration announced a plan to hasten generic drug approvals and thereby increase competition, potentially reducing drug prices altogether.

General Oncology Industry Payments to Physicians: Confronting Conflicts of Interest

Industry Payments to Physicians: Confronting Conflicts of Interest

Though imperiled by efforts to repeal the Affordable Care Act, the federal Open Payments transparency program is helping to expose industry payments to physicians.

Renal Cell Carcinoma Q&A With Roberto Iacovelli, MD: Personalizing Immunotherapy for Renal Cell Carcinoma

Q&A With Roberto Iacovelli, MD: Personalizing Immunotherapy for Renal Cell Carcinoma

In this question-and-answer session, Cancer Therapy Advisor asked Dr Iacovelli about his team's recent review regarding the future of personalizing immunotherapy for RCC.

General Oncology Monoclonal Antibodies as Immunotherapy "Magic Bullets"

Monoclonal Antibodies as Immunotherapy "Magic Bullets"

Many cancers in humans are weakly immunogenic — if immunogenic at all — and overcoming this inherent property of cancer cells will be critical for the future success of cancer immunology.

General Oncology Dermatomyositis and Cancer Risk

Dermatomyositis and Cancer Risk

Treating physicians should watch for any suspicious signs of cancer after DM is diagnosed.

Renal Cell Carcinoma Advanced Renal Cell Carcinoma: Interviews With Neeraj Agarwal, MD, and Ulka Vaishampayan, MD

Advanced Renal Cell Carcinoma: Interviews With Neeraj Agarwal, MD, and Ulka Vaishampayan, MD

Ulka Vaishampayan, MD, and Neeraj Agarwal, MD, spoke with Cancer Therapy Advisor about treatment recommendations for patients newly diagnosed with metastatic RCC.

General Oncology Cancer Treatment Cost-effectiveness: Difficult To Define Due to Perception

Cancer Treatment Cost-effectiveness: Difficult To Define Due to Perception

If value is hard to define because it is perceived differently by different people, how can oncologists and policymakers accurately gauge cost-effectiveness?

Renal Cell Carcinoma In Focus: Cabozantinib for Renal Cell Carcinoma

In Focus: Cabozantinib for Renal Cell Carcinoma

Ongoing studies are expected to provide information about how to sequence cabozantinib in clinical practice.

General Oncology Clinicians Advocate for Patients With Sexual Dysfunction After Cancer, A Quality of Life Issue

Clinicians Advocate for Patients With Sexual Dysfunction After Cancer, A Quality of Life Issue

Clinicians are advocating that sexual dysfunction after cancer, which affects a large proportion of survivors, be addressed as a serious quality of life issue.

General Oncology Q&A With Scott Roberts, PhD: Direct-to-Consumer Cancer Gene Testing

Q&A With Scott Roberts, PhD: Direct-to-Consumer Cancer Gene Testing

In this question-and-answer session, Cancer Therapy Advisor asked Dr Roberts about direct-to-consumer genomic testing for cancer risk.

Renal Cell Carcinoma Q&A With Nilay Shah, MD: Cabozantinib Treatment in Children With Recurrent Metastatic RCC

Q&A With Nilay Shah, MD: Cabozantinib Treatment in Children With Recurrent Metastatic RCC

Cancer Therapy Advisor interviewed Dr Shah regarding 2 recent case studies about pediatric patients with RCC who responded to cabozantinib.

General Oncology Bayesian Adaptive Randomization: A Q&A With Brian M. Alexander MD, PhD

Bayesian Adaptive Randomization: A Q&A With Brian M. Alexander MD, PhD

Researchers developed a novel Bayesian adaptive randomization method that maximizes efficiency by focusing the algorithm to reduce uncertainty within patient-treatment baskets.

General Oncology Random Mutations May Be Leading Cause of Oncogenesis

Random Mutations May Be Leading Cause of Oncogenesis

According to a study across all 32 cancer types, data suggest that 66% of mutations leading to cancer are the result of random events.

General Oncology Proposed US Budget Cuts: Effects on Cancer Research

Proposed US Budget Cuts: Effects on Cancer Research

According to the AACI, proposed budget cuts by the White House would likely mean a cut of close to $1 billion for the National Cancer Institute.

Renal Cell Carcinoma Nivolumab for Advanced Renal Cell Carcinoma: Cost and Value

Nivolumab for Advanced Renal Cell Carcinoma: Cost and Value

As treatment options increase, patient-reported outcomes and cost-effective analyses will play a key role in determining how drugs are sequenced in clinical practice.

General Oncology Immunotherapy in the Twentieth Century: William Coley and Lloyd J. Old

Immunotherapy in the Twentieth Century: William Coley and Lloyd J. Old

Dr Clifford Pukel, a board certified medical oncologist and CEO of the Cancer Vaccine Cancer Immunotherapy (CVCI) foundation, discusses some important moments in the history of immunotherapy.

General Oncology Incorporating Evolutionary Theory Into Oncology

Incorporating Evolutionary Theory Into Oncology

Oncologists, drug developers, and evolutionary theorists could collaborate to design treatments and treatment combinations that are more likely to succeed given the laws of natural selection.

General Oncology Industry Payments Influence Research, Prescribing, and Advocacy

Industry Payments Influence Research, Prescribing, and Advocacy

Clinical trial investigators who receive drug industry funding are about 3.5 times as likely to find positive results as trials led by scientists who did not receive industry payments.

General Oncology Treeomics: A Mathematical Tool for Predicting Metastases

Treeomics: A Mathematical Tool for Predicting Metastases

Researchers recently created a tool, Treeomics, to reconstruct the evolutionary pathway of metastases and to chart subclones to their anatomical locations.

Genitourinary Cancers Symposium 2017 2017 ASCO GU Symposium: Updates in Managing Small Renal Masses

2017 ASCO GU Symposium: Updates in Managing Small Renal Masses

At a general session at the 2017 ASCO GU Symposium, the latest advances in managing SRMs will be discussed.

General Oncology Do Clinical Trials Overstate New Cancer Drugs' Survival Benefits?

Do Clinical Trials Overstate New Cancer Drugs' Survival Benefits?

Experts disagree about whether success in clinical trials translates to success in real world treatment settings.

Renal Cell Carcinoma Biomarkers in Renal Cell Carcinoma: Evidence and Challenges

Biomarkers in Renal Cell Carcinoma: Evidence and Challenges

New and old biomarkers should be included in clinical trials to help build a database from which oncologists can draw sound clinical recommendations.

General Oncology The 21st Century Cures Act: An Unclear Advance

The 21st Century Cures Act: An Unclear Advance

Critics worry that changes to the FDA's drug approval process could lead to increased off-label prescribing and the marketing of questionable therapies.

General Oncology Vitamin D and Cancer: An Unclear Relationship

Vitamin D and Cancer: An Unclear Relationship

According to the National Cancer Institute, there are not enough available data to establish whether taking vitamin D can prevent cancer.

General Oncology Basket Trials: Advantages and Limitations

Basket Trials: Advantages and Limitations

Basket trials offer a cost-effective option to evaluate targeted agents in multiple malignancies, but it is important to be aware of their limitations.

General Oncology Survival After Pediatric Cancer: Reducing the Lifetime Burden

Survival After Pediatric Cancer: Reducing the Lifetime Burden

A study of self-reported health status shows the need for physicians to consider the overall well-being of pediatric cancer survivors, for life.

Renal Cell Carcinoma Kidney Cancer: Statin Use May Improve Disease-specific Survival

Kidney Cancer: Statin Use May Improve Disease-specific Survival

Statin use in patients with kidney cancer improved cancer-specific survival and overall survival.

Renal Cell Carcinoma Rotating Treatments in Renal Cell Carcinoma

Rotating Treatments in Renal Cell Carcinoma

ROPETAR failed to demonstrate any clinical benefit in alternating treatment with pazopanib and everolimus.

Supportive Care Seven States Approve Some Form of Marijuana Initiative

Seven States Approve Some Form of Marijuana Initiative

CTA spoke with Judith A. Paice, PhD, RN, to better understand how clinicians are reacting to these legalizations and how she responds to patients asking about cannabis use.

General Oncology Watson: A Glorified Search Engine?

Watson: A Glorified Search Engine?

Watson, hoped to be a major source for clinicians, is limited by an inability to interpret clinical trials.

General Oncology Is Drugmaker Funding for Patient Groups a Hidden Culprit in Rising Drug Prices?

Is Drugmaker Funding for Patient Groups a Hidden Culprit in Rising Drug Prices?

Drugmaker funding for patient advocacy groups might be an important but neglected factor in rising drug prices.

Supportive Care Precision Medicine in Pediatric Cancer

Precision Medicine in Pediatric Cancer

More research and funding are needed to bring the benefits of precision medicine to pediatric patients.

Renal Cell Carcinoma A View of the Current and Future Treatment Landscapes in Renal Cell Carcinoma

A View of the Current and Future Treatment Landscapes in Renal Cell Carcinoma

Although there was hope that biomarkers may aid in treatment selection, research efforts to date have not yielded a viable option.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs